Selected research
Industry Research
Treatments for Alpha-1 Industry Research Report 2026
Market perspective
The global Treatments for Alpha-1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Treatments for Alpha-1 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Treatments for Alpha-1 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Treatments for Alpha-1 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Treatments for Alpha-1 include Takeda, Teva Pharmaceutical Industries, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, ProMetic Life Sciences and Kedrion Group, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Treatments for Alpha-1 market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Treatments for Alpha-1.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Treatments for Alpha-1 Market by Company
Takeda
Teva Pharmaceutical Industries
Pfizer
GlaxoSmithKline
Baxter
AstraZeneca
Vertex Pharmaceuticals
ProMetic Life Sciences
Kedrion Group
Kamada Ltd
Grifols
CSL Behring
Chiesi Pharmaceuticals
Boehringer Ingelheim
Treatments for Alpha-1 Segment by Type
Augmentation Therapy
Diabetes
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Treatments for Alpha-1 Segment by Application
Hospitals
Specialty Clinics
Pharmacies
Treatments for Alpha-1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatments for Alpha-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Treatments for Alpha-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatments for Alpha-1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Treatments for Alpha-1 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Augmentation Therapy
- Diabetes
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Other
Applications
- Hospitals
- Specialty Clinics
- Pharmacies
Companies covered
- Takeda
- Teva Pharmaceutical Industries
- Pfizer
- GlaxoSmithKline
- Baxter
- AstraZeneca
- Vertex Pharmaceuticals
- ProMetic Life Sciences
- Kedrion Group
- Kamada Ltd
- Grifols
- CSL Behring
- Chiesi Pharmaceuticals
- Boehringer Ingelheim
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Treatments for Alpha-1 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Augmentation Therapy
- 2.2.3 Diabetes
- 2.2.4 Cystic Fibrosis(CF)
- 2.2.5 Non-CF Bronchiectasis(NCFB)
- 2.2.6 Other
- 2.3 Treatments for Alpha-1 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Specialty Clinics
- 2.3.4 Pharmacies
- 2.4 Assumptions and Limitations
3 Treatments for Alpha-1 Breakdown Data by Type
- 3.1 Global Treatments for Alpha-1 Historic Market Size by Type (2021-2026)
- 3.2 Global Treatments for Alpha-1 Forecasted Market Size by Type (2027-2032)
4 Treatments for Alpha-1 Breakdown Data by Application
- 4.1 Global Treatments for Alpha-1 Historic Market Size by Application (2021-2026)
- 4.2 Global Treatments for Alpha-1 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Treatments for Alpha-1 Market Perspective (2021-2032)
- 5.2 Global Treatments for Alpha-1 Growth Trends by Region
- 5.2.1 Global Treatments for Alpha-1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Treatments for Alpha-1 Historic Market Size by Region (2021-2026)
- 5.2.3 Treatments for Alpha-1 Forecasted Market Size by Region (2027-2032)
- 5.3 Treatments for Alpha-1 Market Dynamics
- 5.3.1 Treatments for Alpha-1 Industry Trends
- 5.3.2 Treatments for Alpha-1 Market Drivers
- 5.3.3 Treatments for Alpha-1 Market Challenges
- 5.3.4 Treatments for Alpha-1 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Treatments for Alpha-1 Players by Revenue
- 6.1.1 Global Top Treatments for Alpha-1 Players by Revenue (2021-2026)
- 6.1.2 Global Treatments for Alpha-1 Revenue Market Share by Players (2021-2026)
- 6.2 Global Treatments for Alpha-1 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Treatments for Alpha-1 Head Office and Area Served
- 6.4 Global Treatments for Alpha-1 Players, Product Type & Application
- 6.5 Global Treatments for Alpha-1 Manufacturers Established Date
- 6.6 Global Treatments for Alpha-1 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Treatments for Alpha-1 Market Size (2021-2032)
- 7.2 North America Treatments for Alpha-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Treatments for Alpha-1 Market Size by Country (2021-2026)
- 7.4 North America Treatments for Alpha-1 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Treatments for Alpha-1 Market Size (2021-2032)
- 8.2 Europe Treatments for Alpha-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Treatments for Alpha-1 Market Size by Country (2021-2026)
- 8.4 Europe Treatments for Alpha-1 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Treatments for Alpha-1 Market Size (2021-2032)
- 9.2 Asia-Pacific Treatments for Alpha-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Treatments for Alpha-1 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Treatments for Alpha-1 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Treatments for Alpha-1 Market Size (2021-2032)
- 10.2 South America Treatments for Alpha-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Treatments for Alpha-1 Market Size by Country (2021-2026)
- 10.4 South America Treatments for Alpha-1 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Treatments for Alpha-1 Market Size (2021-2032)
- 11.2 Middle East & Africa Treatments for Alpha-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Treatments for Alpha-1 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Treatments for Alpha-1 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.1.4 Takeda Treatments for Alpha-1 Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Teva Pharmaceutical Industries
- 12.2.1 Teva Pharmaceutical Industries Company Information
- 12.2.2 Teva Pharmaceutical Industries Business Overview
- 12.2.3 Teva Pharmaceutical Industries Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.2.4 Teva Pharmaceutical Industries Treatments for Alpha-1 Product Portfolio
- 12.2.5 Teva Pharmaceutical Industries Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.3.4 Pfizer Treatments for Alpha-1 Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 GlaxoSmithKline
- 12.4.1 GlaxoSmithKline Company Information
- 12.4.2 GlaxoSmithKline Business Overview
- 12.4.3 GlaxoSmithKline Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.4.4 GlaxoSmithKline Treatments for Alpha-1 Product Portfolio
- 12.4.5 GlaxoSmithKline Recent Developments
- 12.5 Baxter
- 12.5.1 Baxter Company Information
- 12.5.2 Baxter Business Overview
- 12.5.3 Baxter Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.5.4 Baxter Treatments for Alpha-1 Product Portfolio
- 12.5.5 Baxter Recent Developments
- 12.6 AstraZeneca
- 12.6.1 AstraZeneca Company Information
- 12.6.2 AstraZeneca Business Overview
- 12.6.3 AstraZeneca Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.6.4 AstraZeneca Treatments for Alpha-1 Product Portfolio
- 12.6.5 AstraZeneca Recent Developments
- 12.7 Vertex Pharmaceuticals
- 12.7.1 Vertex Pharmaceuticals Company Information
- 12.7.2 Vertex Pharmaceuticals Business Overview
- 12.7.3 Vertex Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.7.4 Vertex Pharmaceuticals Treatments for Alpha-1 Product Portfolio
- 12.7.5 Vertex Pharmaceuticals Recent Developments
- 12.8 ProMetic Life Sciences
- 12.8.1 ProMetic Life Sciences Company Information
- 12.8.2 ProMetic Life Sciences Business Overview
- 12.8.3 ProMetic Life Sciences Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.8.4 ProMetic Life Sciences Treatments for Alpha-1 Product Portfolio
- 12.8.5 ProMetic Life Sciences Recent Developments
- 12.9 Kedrion Group
- 12.9.1 Kedrion Group Company Information
- 12.9.2 Kedrion Group Business Overview
- 12.9.3 Kedrion Group Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.9.4 Kedrion Group Treatments for Alpha-1 Product Portfolio
- 12.9.5 Kedrion Group Recent Developments
- 12.10 Kamada Ltd
- 12.10.1 Kamada Ltd Company Information
- 12.10.2 Kamada Ltd Business Overview
- 12.10.3 Kamada Ltd Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.10.4 Kamada Ltd Treatments for Alpha-1 Product Portfolio
- 12.10.5 Kamada Ltd Recent Developments
- 12.11 Grifols
- 12.11.1 Grifols Company Information
- 12.11.2 Grifols Business Overview
- 12.11.3 Grifols Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.11.4 Grifols Treatments for Alpha-1 Product Portfolio
- 12.11.5 Grifols Recent Developments
- 12.12 CSL Behring
- 12.12.1 CSL Behring Company Information
- 12.12.2 CSL Behring Business Overview
- 12.12.3 CSL Behring Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.12.4 CSL Behring Treatments for Alpha-1 Product Portfolio
- 12.12.5 CSL Behring Recent Developments
- 12.13 Chiesi Pharmaceuticals
- 12.13.1 Chiesi Pharmaceuticals Company Information
- 12.13.2 Chiesi Pharmaceuticals Business Overview
- 12.13.3 Chiesi Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.13.4 Chiesi Pharmaceuticals Treatments for Alpha-1 Product Portfolio
- 12.13.5 Chiesi Pharmaceuticals Recent Developments
- 12.14 Boehringer Ingelheim
- 12.14.1 Boehringer Ingelheim Company Information
- 12.14.2 Boehringer Ingelheim Business Overview
- 12.14.3 Boehringer Ingelheim Revenue in Treatments for Alpha-1 Business (2021-2026)
- 12.14.4 Boehringer Ingelheim Treatments for Alpha-1 Product Portfolio
- 12.14.5 Boehringer Ingelheim Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst